Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 256 clinical trials
None
Risperidone for the Treatment of Huntington's Disease Involuntary Movements

The purpose of this study is to assess the safety and benefit of risperidone for the treatment of chorea (involuntary movements) in Huntington's disease. Risperidone is commonly used in clinical

involuntary movements
chorea
risperidone
  • 0 views
  • 14 Nov, 2021
  • 1 location
None
Efficacy and Safety of Deep Brain Stimulation (DBS) of the Pallidal (GPi) in Patients With Tardive Dystonia

The purpose of this randomized, double blind, multi-center study is to assess the efficacy and safety of bilateral pallidal deep brain stimulation in patients with tardive dystonia.

dystonia
dyskinesia
deep brain stimulation
brain stimulation
  • 68 views
  • 07 Nov, 2020
  • 1 location
None
  • 0 views
  • 27 Oct, 2021
  • 1 location
None
Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components

This is a two-part, double-blind, placebo-controlled, randomized, multicenter Phase 2 clinical trial of JM-010 in patients with Parkinson's Disease.

parkinson's disease
dyskinesia
levodopa
  • 3 views
  • 16 Nov, 2021
  • 15 locations
None
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy

This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and

parkinson's disease
dyskinesia
movement disorder
levodopa
  • 0 views
  • 10 Oct, 2021
  • 26 locations
None
Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy

This open-label study is designed to assess the long-term safety and tolerability of dipraglurant in PD patients for up to 52 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day) for patients that have completed an Addex sponsored double-blind clinical trial of dipraglurant.

parkinson's disease
levodopa
  • 0 views
  • 19 Nov, 2021
  • 1 location
None
Neurophysiological Behavioral and Cognitive Networks in Movement Disorders

The purpose of this study is to investigate the brain activity associated with motor and non-motor symptoms of movement disorders, including Parkinson's disease (PD) and essential tremor. These movement disorders commonly have significant non-motor features, such as depression, cognitive and memory impairment, decreased attention, speech and language disturbances, and slower …

parkinson's disease
essential tremor
deep brain stimulation
depression
tremor
  • 0 views
  • 02 Jul, 2021
  • 1 location
None
Double Randomized and Placebo Controlled Trail of Tianqi Pingchan Granule to Prevent Levodopa-Induced Dyskinesia

induced dyskinesia, so as to determine the clinical efficacy of Tianqi Pingzhan Granule in the prevention of levodopa induced dyskinesia.

  • 2 views
  • 23 Jan, 2021
  • 1 location
None
Clinical Study on Treatment of L-DOPA-Induced Dyskinesia With Tianqi Pingchan Granule Combined With Amantadine

A randomized, double-blind, placebo-controlled, multi-center clinical trial was conducted to observe the improvement in the level of dyskinesia in patients with Parkinson's disease during the 12

  • 0 views
  • 27 Jan, 2021
  • 1 location
None
Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype

The purpose of this study is to measure mucociliary clearance (MCC) in groups of subjects with the disease Primary Ciliary Dyskinesia (PCD) caused by mutations in different genes. Some of these

  • 0 views
  • 10 Jul, 2021
  • 1 location